跳至主要内容
临床试验/NCT05981885
NCT05981885已完成不适用

68Ga-FAPI PET/CT to Detect Ongoing Fibroblast Activity in Post-acute COVID-19 With Respiratory Impairment After Hospital Discharge

University Medical Center Groningen1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2022年6月9日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
18
试验地点
1
主要终点
Pulmonary SUV values

研究概览

简要总结

The goal of this observational study is to investigate the role fibroblasts play in the persistent respiratory complaints after a COVID-19 infection. Fibroblasts are involved in tissue remodeling and repair by creating scar-tissue (fibrosis) after tissue damage has occurred. The hypothesis is that this process of fibrosis is ongoing in patients with persistent complaints. To evaluate the roll of fibroblasts a new type of scan is used that is capable of imaging active fibroblasts, a 68Ga-FAPI PET/CT scan.

详细描述

Rationale: The pathogenesis of post-acute COVID-19 with respiratory complaints remains unknown. We aim to explore the pulmonary pattern and fibrosis activity in patients with post-acute COVID-19 with respiratory complaints using 68Ga-FAPI Positron Emission Tomography-Computed Tomography (PET/CT) imaging.

Objective

To relate pulmonary fibroblast activity, measured by FAPI-PET/CT at least 3 months after hospital discharge, to interstitial lung abnormalities on high resolution CT (HRCT) at the same time point in post-acute COVID-19 patients with respiratory complaints.

Study design: This is a ZonMw funded single center prospective observational cohort study of post-acute COVID-19 patients with respiratory complaints.

Study population: We will recruit 20 adult patients, all post-ICU or post High-Flow Nasal Oxygen therapy due to there COVID-19 infection, with post-acute COVID-19 and respiratory complaints that will undergo 68Ga-FAPI PET/CT imaging to establish pulmonary fibrosis activity.

Main study parameters/endpoints: To assess the degree of Fibroblast Activation Protein expression on 68Ga-FAPI PET/CT at least 3 months after hospital discharge and to relate this to interstitial lung abnormalities on HRCT at the same time point.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male patients >18 years and female patients >20 years discharged from hospital after PCR-confirmed COVID-19 infection.
  • Previous ICU or ward admission with high flow nasal oxygen (HFNO) or mechanical ventilation.
  • Persistent respiratory complaints (shortness of breath) at least 3 months after hospital discharge.

排除标准

  • Inability or unwilling to give informed consent.
  • History of claustrophobia or feeling of inability to tolerate supine position for the PET/CT scans.
  • Severe or significant comorbidity, defined as COPD GOLD stage II or higher and/or known interstitial lung disease.
  • Women who are pregnant or breastfeeding.

结局指标

主要结局

Pulmonary SUV values

时间窗: At time of inclusion (T0)

Based on the FAPI PET/CT scan 3-dimensinal volumes of intrest (VOI) are drawn of high FAPI uptake areas (leasions) and non-uptake areas. Using these VOIs SUV values and metabolic active volume (MAV) can be calculated which then can be used to calculate: total lesion FAPI (TL-FAPI), whole-lung FAPI-MAV (wl FAPI-MAV), wlSUVmean and whole lung TL-FAPI (wlTL-FAPI).

次要结局

  • HRCT(At time of inclusion (T0))
  • 6 minute walking test vs pulmonary SUV values(At time of inclusion (T0))
  • Follow-up daily impairments (EQ-5D questionnaire) vs pulmonary SUV values(10 months after T0)
  • Follow-up HRCT(10 months after T0)
  • DCLO and VC vs pulmonary SUV values(At time of inclusion (T0))
  • Cellular phenotypes(At time of inclusion (T0))
  • Correlate biomarkers to pulmonary SUV values(At time of inclusion (T0))
  • Daily impairments (EQ-5D questionnaire) vs pulmonary SUV values(At time of inclusion (T0))

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验